Author

Bjoern Schwalb

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 3 Cancer Biology· 1 Genomics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Organism:human· 4 Approach:experimental assay· 3 Assay:proteomics· 3 Approach:deep learning· 2 Approach:statistical model· 2 Assay:ATAC-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

Bachuki ShashikadzeiD· 4 shared Henrik DaubiD· 4 shared Martin StegeriD· 4 shared Uli OhmayeriD· 4 shared Anastasia Bednarz· 3 shared Denis Bartoschek· 3 shared Denise Winkler· 3 shared Patrick R. A. ZanoniD· 3 shared

Activity by Year

2016-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

Bachuki ShashikadzeORCID

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Discovery of CDK4-selective molecular glue degraders by high-throughput proteomics

Patrick R. A. Zanon, Bachuki Shashikadze, Denise Winkler, Ines F. Scheller, Denis Bartoschek, Anastasia Bednarz, Tobias Graef, Sophie Machata, Uli Ohmayer, Bjoern Schwalb, Martin Steger, Henrik Daub

This study identifies a CDK4-selective molecular glue degrader, NE26394, using high-throughput proteomics, showing its efficacy in CDK4-dependent cancer models.

bioRxiv · Jun 22, 2026 · PreprintBiochemistry

Integrated proteomic screening reveals design principles of CRBN molecular glue degraders

Bachuki Shashikadze, Ines F. Scheller, Denise Winkler, Patrick R. A. Zanon, Anastasia Bednarz, Denis Bartoschek, Sophie Machata, Tobias Graef, Uli Ohmayer, Bjoern Schwalb, Henrik Daub, Martin Steger

The paper identifies new CRBN neosubstrates using proteomic screening and machine learning, expanding the landscape of molecular glue degraders.

bioRxiv · Mar 10, 2026 · PreprintBiochemistry

Developing Potent and Selective TBK1 Molecular Glue Degraders for Cancer Immunotherapy

John Caldwell, Patrick R. A. Zanon, Iona Ferguson, Stephen T. Hallett, Tencho Tenev, Natalia Serrano-Aparicio, Russell J.H. Wood, Shakil Khan, Sidonie Wicky John, Rebecca Wilson, Matthew T. Warren, P. Craig McAndrew, Martin Steger, Denise Winkler, Uli Ohmayer, , Zoran Ranković

This paper develops a first-in-class TBK1 molecular glue degrader, CCT412020, which enhances anti-tumour immunity and overcomes immune checkpoint blockade resistance.

bioRxiv · Feb 2, 2026 · PreprintCancer Biology

Unbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics

Martin Steger, Gisele Nishiguchi, Qiong Wu, Bjoern Schwalb, Bachuki Shashikadze, Kevin M. McGowan, Marisa Actis, Anup Aggarwal, Zhe Shi, Jeanine E. Price, Anand Mayasundari, Lei Yang, Anastasia Bednarz, Sophie Machata, Tobias Graef, , Zoran Ranković

Proteomics and ubiquitinomics screening of 100 CRBN ligands in two cell lines validated 50 novel neosubstrates and yielded selective phenyl glutarimide degraders of KDM4B, G3BP2 and VCL.

Nature Communications · Aug 20, 2025Peer-reviewedBiochemistry✦ In-depth digest

Accurate promoter and enhancer identification in 127 ENCODE and Roadmap Epigenomics cell types and tissues by GenoSTAN

Benedikt Zacher, Margaux Michel, Bjoern Schwalb, Patrick Cramer, Achim Tresch, Julien Gagneur

GenoSTAN improves promoter and enhancer identification in 127 cell types and tissues, showing higher accuracy and better enrichment of genetic variants.

bioRxiv · Mar 6, 2016Genomics